NCT07502508: Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
- State
- Under way
- Phase
- Phase 2
- People
- 60 planned
- Started
- 30 Apr 2026
- Primary completion
- Jun 2027
- Arms
- Arm A: icovamenib 100 mg
- Results
- None posted
- 31 Mar 2026: Trial registered
- 30 Apr 2026: Trial started